Atara Biotherapeutics Financials

ATRA Stock  USD 0.80  0.09  12.68%   
Based on the key indicators related to Atara Biotherapeutics' liquidity, profitability, solvency, and operating efficiency, Atara Biotherapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March. At present, Atara Biotherapeutics' Receivables is projected to increase significantly based on the last few years of reporting. The current year's Assets Non Current is expected to grow to about 100.9 M, whereas Accounts Payable is forecasted to decline to about 5.7 M. Key indicators impacting Atara Biotherapeutics' financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Return on Equity(1.06)(1.03)
Fairly Down
Slightly volatile
Debt to Equity Ratio2.452.27
Significantly Up
Slightly volatile
Current Ratio3.463.37
Fairly Up
Slightly volatile
The financial analysis of Atara Biotherapeutics is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for Atara Biotherapeutics includes many different criteria found on its balance sheet. For example, investors should never minimize Atara Biotherapeutics' ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor Atara Biotherapeutics' cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in Atara Biotherapeutics.

Cash and Equivalents

100.37 Million

With this module, you can analyze Atara financials for your investing period. You should be able to track the changes in Atara Biotherapeutics individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
  
Understanding current and past Atara Biotherapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Atara Biotherapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Atara Biotherapeutics' assets may result in an increase in income on the income statement.
Evaluating Atara Biotherapeutics' financials involves analyzing a range of financial metrics and ratios to gain insights into the company's financial health and performance. However, considering all of Atara Biotherapeutics' profitability, liquidity ratios, and efficiency indicators at the same time could be an enormous task, and our Financial Distress score can provide you with a snapshot of the Atara Biotherapeutics' relative financial performance

Chance Of Distress

Over 73

 
100  
 
Zero
High
Atara Biotherapeutics has more than 73 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Atara Biotherapeutics stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity.
Please note, Atara Biotherapeutics' odds of distress score SHOULD NOT be confused with the real chance of Atara Biotherapeutics filing for bankruptcy protection for chapters 7, 11, 12, or 13. We define Financial Distress as an operational condition where an entity such as Atara is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from public financial statements and analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors considered include Atara Biotherapeutics' liquidity analysis, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
More Info
The data published in Atara Biotherapeutics' official financial statements usually reflect Atara Biotherapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Atara Biotherapeutics. For example, before you start analyzing numbers published by Atara accountants, it's critical to develop an understanding of what Atara Biotherapeutics' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Atara Biotherapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Atara Biotherapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Atara Biotherapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Atara Biotherapeutics. Please utilize our Beneish M Score to check the likelihood of Atara Biotherapeutics' management manipulating its earnings.

Atara Biotherapeutics Company Summary

Atara Biotherapeutics competes with A SPAC, National Health, Evertz Technologies, Arrow Electronics, and Joint Corp. Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company was incorporated in 2012 and is headquartered in South San Francisco, California. Atara Biotherap operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 578 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
CIK Number0001604464
ISINUS0465131078
CUSIP046513107
RegionNorth America
LocationCalifornia; U.S.A
Business Address2380 Conejo Spectrum
SectorBiotechnology
IndustryHealth Care
BenchmarkNYSE Composite
Websitewww.atarabio.com
Phone805 623 4211
CurrencyUSD - US Dollar
You should never invest in Atara Biotherapeutics without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Atara Stock, because this is throwing your money away. Analyzing the key information contained in Atara Biotherapeutics' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Atara Biotherapeutics Key Financial Ratios

Generally speaking, Atara Biotherapeutics' financial ratios allow both analysts and investors to convert raw data from Atara Biotherapeutics' financial statements into concise, actionable information that can be used to evaluate the performance of Atara Biotherapeutics over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Atara Biotherapeutics reports annually and quarterly.

Atara Biotherapeutics Key Income Statement Accounts

An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket. The other reason investors look at the income statement is to determine what Atara Biotherapeutics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
201920202021202220232024 (projected)
Consolidated Income(291.0M)(306.6M)(340.1M)(228.3M)(205.5M)(221.7M)
Earning Before Interest and Taxes EBIT(295.7M)(309.1M)(340.5M)(230.3M)(207.2M)(223.6M)
Earning Before Interest and Taxes USD(295.7M)(309.1M)(340.5M)(230.3M)(207.2M)(223.6M)
Interest Expense(4.7M)(2.4M)(367K)(2.0M)(1.8M)(1.9M)
Net Income(291.0M)(306.6M)(340.1M)(228.3M)(205.5M)(221.7M)
Net Income Common Stock(291.0M)(306.6M)(340.1M)(228.3M)(205.5M)(221.7M)
Net Income Common Stock USD(291.0M)(306.6M)(340.1M)(228.3M)(205.5M)(221.7M)
Operating Expenses295.7M309.1M360.8M344.1M395.7M315.1M
Operating Income(295.7M)(309.1M)(340.5M)(280.5M)(252.5M)(272.4M)
Research and Development Expense216.1M244.7M282.0M272.5M313.4M338.2M
Selling General and Administrative Expense79.6M64.4M78.8M71.6M82.3M70.1M
Weighted Average Shares51.3M74.0M93.7M102.0M117.3M126.5M
Weighted Average Shares Diluted51.3M74.0M93.7M102.0M117.3M126.5M
Income Tax Expense(44K)12K15K46K10.8K13.0K

Atara Biotherapeutics Key Cash Accounts

Cash flow analysis captures how much money flows into and out of Atara Biotherapeutics. It measures of how well Atara is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Atara Biotherapeutics brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Atara had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Atara Biotherapeutics has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
201920202021202220232024 (projected)
Capital Expenditure(5.6M)(4.5M)(10.6M)90.6M104.2M112.4M
Depreciation Amortization and Accretion8.0M9.8M11.3M14.6M16.8M18.1M
Net Cash Flow or Change in Cash and Cash Equivalents13.6M126.1M(94.3M)(14.4M)(13.0M)(13.3M)
Issuance Purchase of Equity Shares188.6M423.0M98.7M21.9M19.7M20.2M
Issuance Repayment of Debt Securities(486K)(389K)(254K)30.1M34.6M37.3M
Net Cash Flow from Financing188.8M427.6M103.9M53.1M61.0M62.7M
Net Cash Flow from Investing60.5M(120.7M)22.3M203.0M233.4M251.8M
Net Cash Flow Investment Acquisitions and Disposals66.0M(116.2M)32.8M112.4M129.2M139.4M
Net Cash Flow from Operations(235.6M)(180.8M)(220.5M)(270.4M)(243.4M)(249.8M)
Share Based Compensation51.7M51.4M53.9M53.8M61.9M50.3M

Atara Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Atara Biotherapeutics's current stock value. Our valuation model uses many indicators to compare Atara Biotherapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Atara Biotherapeutics competition to find correlations between indicators driving Atara Biotherapeutics's intrinsic value. More Info.
Atara Biotherapeutics is number one stock in shares outstanding category among related companies. It is number one stock in current ratio category among related companies . The ratio of Shares Outstanding to Current Ratio for Atara Biotherapeutics is about  19,303,409 . At present, Atara Biotherapeutics' Current Ratio is projected to decrease significantly based on the last few years of reporting.. Comparative valuation analysis is a catch-all model that can be used if you cannot value Atara Biotherapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Atara Biotherapeutics' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Atara Biotherapeutics' earnings, one of the primary drivers of an investment's value.

Atara Biotherapeutics Systematic Risk

Atara Biotherapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Atara Biotherapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Atara Biotherapeutics correlated with the market. If Beta is less than 0 Atara Biotherapeutics generally moves in the opposite direction as compared to the market. If Atara Biotherapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Atara Biotherapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Atara Biotherapeutics is generally in the same direction as the market. If Beta > 1 Atara Biotherapeutics moves generally in the same direction as, but more than the movement of the benchmark.
.

About Atara Biotherapeutics Financials

What exactly are Atara Biotherapeutics Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Atara Biotherapeutics' income statement, its balance sheet, and the statement of cash flows. Potential Atara Biotherapeutics investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Atara Biotherapeutics investors may use each financial statement separately, they are all related. The changes in Atara Biotherapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Atara Biotherapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.

Steps to analyze Atara Biotherapeutics Financials for Investing

There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Atara Biotherapeutics is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Atara has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.
In summary, you can determine if Atara Biotherapeutics' financials are consistent with your investment objective using the following steps:
  • Review Atara Biotherapeutics' balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
  • Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
  • Study the cash flow inflows and outflows to understand Atara Biotherapeutics' liquidity and solvency.
  • Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
  • Compare Atara Biotherapeutics' financials to those of its peers to see how it stacks up and identify any potential red flags.
  • Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Atara Biotherapeutics' stock is overvalued or undervalued.
Remember, these are just guidelines and should not be the only basis for investment decisions. It is always important to analyze the leading stock market indicators., conduct additional research and seek professional advice if needed.

Atara Biotherapeutics Thematic Clasifications

Atara Biotherapeutics is part of Cancer Fighters investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Public companies from health care and pharmaceutical sectors that are focused on fighting cancer. Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases
Cancer FightersView
This theme covers Public companies from health care and pharmaceutical sectors that are focused on fighting cancer. Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases. Get More Thematic Ideas

Atara Biotherapeutics February 28, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Atara Biotherapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Atara Biotherapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Atara Biotherapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Atara Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Atara Biotherapeutics's daily price indicators and compare them against related drivers.
When determining whether Atara Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Atara Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Atara Biotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Atara Biotherapeutics Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Atara Biotherapeutics. Also, note that the market value of any Company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For information on how to trade Atara Stock refer to our How to Trade Atara Stock guide.
You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.

Complementary Tools for Atara Stock analysis

When running Atara Biotherapeutics' price analysis, check to measure Atara Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atara Biotherapeutics is operating at the current time. Most of Atara Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Atara Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atara Biotherapeutics' price. Additionally, you may evaluate how the addition of Atara Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
CEOs Directory
Screen CEOs from public companies around the world
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Is Atara Biotherapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Atara Biotherapeutics. If investors know Atara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Atara Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.78)
Revenue Per Share
0.043
Quarterly Revenue Growth
(0.52)
Return On Assets
(0.64)
Return On Equity
(4.26)
The market value of Atara Biotherapeutics is measured differently than its book value, which is the value of Atara that is recorded on the company's balance sheet. Investors also form their own opinion of Atara Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Atara Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atara Biotherapeutics' market value can be influenced by many factors that don't directly affect Atara Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atara Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Atara Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atara Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.